1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow Advanced NSCLC: new trials by email Literature Review of Advanced NSCLC trials Research Report on Advanced NSCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC camrelizumab + famitinib, famitinib, docetaxel - Advanced NSCLC | Phase 3 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 1 | 2022-01-06 | 2023-08-16 |
Docetaxel (1) · camrelizumab (1) · famitinib (1)
Jiangsu HengRui Medicine Co., Ltd. (1)
China (1)